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Abstract Imaging or tissue biomarker evidence has been in-
troduced into the core diagnostic pathway for Alzheimer’s
disease (AD). PET using 18F-labelled beta-amyloid PET
tracers has shown promise for the early diagnosis of AD.
However, most studies included only small numbers of par-
ticipants and no consensus has been reached as to which ra-
diotracer has the highest diagnostic accuracy. First, we per-
formed a systematic review of the literature published be-
tween 1990 and 2014 for studies exploring the diagnostic
accuracy of florbetaben, florbetapir and flutemetamol in AD.
The included studies were analysed using the QUADAS as-
sessment of methodological quality. A meta-analysis of the
sensitivity and specificity reported within each study was per-
formed. Pooled values were calculated for each radiotracer
and for visual or quantitative analysis by population included.
The systematic review identified nine studies eligible for
inclusion. There were limited variations in the methods be-
tween studies reporting the same radiotracer. The meta-
analysis results showed that pooled sensitivity and specificity
values were in general high for all tracers. This was confirmed
by calculating likelihood ratios. A patient with a positive ratio
is much more likely to have AD than a patient with a negative
ratio, and vice versa. However, specificity was higher when
only patients with AD were compared with healthy controls.
This systematic review and meta-analysis found no marked
differences in the diagnostic accuracy of the three beta-
amyloid radiotracers. All tracers perform better when used to
discriminate between patients with AD and healthy controls.
The sensitivity and specificity for quantitative and visual anal-
ysis are comparable to those of other imaging or biomarker
techniques used to diagnose AD. Further research is required
to identify the combination of tests that provides the highest
sensitivity and specificity, and to identify the most suitable
position for the tracer in the clinical pathway.
Keywords Florbetapir . Florbetaben . Flutemetamol .
Amyloid . PET . Alzheimer’s disease
Introduction
The 2007 International Working Group (IWG) for New
Research Criteria for the Diagnosis of Alzheimer’s disease
marked a conceptual change. The traditional view of
Alzheimer’s disease (AD) as a purely clinicopathological en-
tity changed to one of AD as a clinicobiological entity. This in
turn led to the introduction of imaging or tissue biomarker
evidence into the core diagnostic pathway [1]. The inclusion
of this evidence enabled diagnosis to be extended to earlier
stages of AD, opening the way for the development of thera-
pies earlier in the course of the disease when clinical
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symptoms are absent [2]. In recent years there has been in-
creasing interest in the use of beta-amyloid PET radiotracers
for the diagnosis of AD.
The clinical features of AD include amnesic memory im-
pairment, language deterioration and visuospatial deficits, as
well as functional and behavioural changes [1, 3]. The original
criteria for diagnosing AD were established in the autumn of
1983 [2, 4]. These criteria, commonly referred to as the
NINCDS-ADRDA criteria, have been used for almost
30 years, provide a sensitivity of 81 % and a specificity of
70 % [3, 5] and are widely used in clinical trials and in clinical
research. According to these criteria the diagnosis of AD is
categorized as probable, possible, and definite [2, 4].
Although the diagnosis of probable and possible AD can be
established clinically, a definite diagnosis requires histopath-
ological confirmation [2, 4]. These criteria were revised in
2011 to include core clinical criteria for probable and possible
(known as mild cognitive impairment, MCI, in the new ver-
sion) AD, and the rationale for including imaging and tissue
biomarkers of the pathophysiological process of AD in the
diagnostic criteria was outlined. These biomarkers were divid-
ed into two classes on a biological basis: biomarkers of brain
amyloid-beta protein deposition and positive PET amyloid
imaging [4, 6].
In the literature, there are multiple potential diagnostic ra-
diotracers at different stages of development. Pittsburgh
Compound B (PiB) is a modification of thioflavin-T, a histo-
logical dye used to bind to amyloid plaques in vitro [7]. 11C-
labelled PiB has been shown to cross the blood–brain barrier
and bind to amyloid plaques with high affinity in vivo in an
animal study [7], and studies in human subjects have demon-
strated its ability to distinguish between patients with AD and
healthy controls (HC) [8, 9]. 11C-PiBmay also be beneficial in
identifying patients in whom MCI will progress to AD [10,
11] and two case studies have demonstrated a relationship
between 11C-PiB retention and post-mortem pathological
findings [12, 13]. However, due to the 20-min half-life of
11C, 11C-PiB can only be used in large PET centres with their
own on-site cyclotron and radiopharmacy facilities.
18F is a more suitable radioisotope for widespread clinical
use as its longer half-life of 110 min allows distribution from a
production site to multiple PET centres. Three 18F-labelled
tracers have been developed which are starting to be used
clinically. Flutemetamol (GE Healthcare) is a close structural
analogue of 11C-PiB, whilst florbetapir (Amyvid, Eli Lilly)
and florbetaben (Neuraceq, Piramal Imaging Limited) are de-
rived from stilbene [14]. Marketing authorizations were
granted by the European Medicines Agency for florbetapir
in 2013 [15], and for florbetaben and flutemetamol in 2014
[16, 17].
We performed a systematic review of published studies that
explored the diagnostic accuracy of the amyloid tracers which
have European marketing authorization. For the purposes of
defining the comparator, we assumed that standard care in-
cludes clinical diagnosis or histopathology results. We also
investigated the quality of the available studies, compared
their technical characteristics and performed a meta-analysis
to examine the investigated tracer’s sensitivity and specificity
for detecting AD.
Methods
Study identification and selection
The criteria for including studies were as follows:
– Includes patients with a diagnosis of AD and a control
group
– Analysis includes more than ten patients
– Investigation of the diagnostic accuracy of florbetapir,
florbetaben or flutemetamol PET uptake compared to
clinical diagnosis or histopathology
– Publication of full paper in a peer-reviewed scientific
journal
Search methods
The literature search was carried out usingMEDLINE (1946 –
week 25 2014; Ovid interface), EMBASE (1947 – week 25
2014; Ovid interface) and the Cochrane Library for relevant
studies published between January 1990 and June 2014.
MEDLINE was additionally searched using the PubMed in-
terface using the tracer name only. Terms designed to identify
the disease, PET tracers and diagnostic accuracy were used
within the search strategy. Supplementary Table S1 shows the
full electronic search strategy used for MEDLINE. The search
was restricted to studies in humans and papers presented in
English. Full text publications were obtained and reviewed.
When multiple publications presented results using the same
patient cohort, the most recent or the most complete publica-
tion was selected for inclusion. Review articles and references
from accepted articles were searched for any additional
papers.
Data extraction and management
Details of the included studies are presented in Tables 1, 2
and 3. The data collected included the overall study char-
acteristics, technical details of the PET acquisition and the
characteristics relevant to the diagnostic accuracy of the
PET scans. The data relevant to diagnostic accuracy are
presented in Table 4. Microsoft Excel software was used
for data collection and management.
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The data fields to extract from the publications were chosen
according to two criteria: the information required to perform
quantitative analysis on the data, and those required to repli-
cate the study design, as described in the modified Quality
Assessment of Diagnostic Accuracy Studies (QUADAS) tool
[26].
QUADAS assessment of methodological quality
The QUADAS tool was developed and evaluated by Whiting
et al. [26, 27] and is recommended by the Cochrane diagnostic
accuracy systematic reviews [28] to provide a methodological
assessment of the quality of studies of diagnostic accuracy.
The tool comprises 14 questions designed to identify potential
areas of bias within a study, and can be tailored to suit the
design of the included studies. The original and a modified
QUADAS list for PET radiotracers [29] were reviewed by two
investigators (A.C., A.H.) and a consensus was agreed regard-
ing the guidelines for scoring each item (Supplementary
Table S1). The ‘reference standard’ was either clinical diag-
nosis or histopathology, and the ‘index test’ was the PET scan
with the radiotracer used in the publication in question. Two of
the questions were not relevant, and were removed from the
list. Each item in the list was scored as ‘yes’ if all aspects of the
criteria were fulfilled, ‘no’ if there were aspects of the criteria
missing, and ‘unclear’ if it was not possible to conclude either
way from the evidence presented in the publication. Two as-
sessors (E.M., A.C.) independently reviewed and scored the
selected publications. Any disagreements were resolved by
discussion and the final scores represent the consensus. The
Table 1 Procedures used in the included studies
Reference Radiopharmaceutical Dose
(MBq)
Reference tests MRI PET scanner Immobilization
devices
Uptake
period
(min)
Scan
duration
(min)
[18] Florbetaben 300±60 NINCDS-ADRDA
criteria, CDR, CERAD
test battery, other
cognitive tests
Yes Stand-alone PET or
PET/CT scanner,
models not specified
Yes 90 20
[19] Florbetapir 4/kg NINCDS-ADRDA
criteria, MMSE,
FCSRT, other
cognitive tests
Yes Philips Dual Gemini,
GE Discovery RX
VCT 64, Siemens
Biograph 6 TruePoint
HiRez
NA 50 10
[20] Florbetapir 370 Post-mortem analysis
using modified
CERAD criteria
No Stand-alone PET or
PET/CT scanner,
models not specified
NA 50 10
[14] Flutemetamol 197±5.9 NIA-AA criteria,
MMSE, CDR, other
cognitive tests
Yes Siemens ECATACCEL
scanner
Yes 85 30
[21] Florbetapir 365 NINCDS-ADRDA
criteria, MMSE,
CDR, other
cognitive tests
Yes Siemens Biograph
mCT PET/CT
NA 50 10
[22] Florbetapir 370 NINCDS-ADRDA
criteria, MMSE
No Not specified Yes 50 10
[23] Florbetapir 370 NINCDS-ADRDA
criteria, MMSE,
demographic
information
No Siemens Biograph 2-slice
PET/CT, Siemens
Biograph mCT 40-slice
PET/CT, Siemens
ECAT HR+
NA 50 10
[24] Flutemetamol 120a or 185 NINCDS-ADRDA
criteria, MMSE, CDR,
other cognitive tests
Yes Siemens Biograph 16-slice
PET/CT, Siemens
ECAT EXACT
HR+ scanner, GE
Advance scanner
NA 85 30
[25] Florbetaben 300 NINCDS-ADRDA
criteria, MMSE, CRS,
other cognitive tests
Yes Philips Allegro Yes 90 20
CDR Clinical Dementia Rating, CERAD Consortium to Establish a Registry for Alzheimer’s disease, FCRST Free and Cued Selective Reminding Test,
MMSEMini-Mental State Examination, NA not available, NIA-AA National Institute on Aging – Alzheimer’s Association, NINCDS-ADRDA National
Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Association
a Subjects who underwent two scans received a lower dose of 120 MBq
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meta-analysis was performed independently of the results of
the QUADAS assessment, as the QUADAS tool was not de-
signed to weight data for this purpose [30, 31].
Meta-analysis
The included studies were reviewed and outcome data were
extracted for the meta-analysis. Given the small study sample
size coupled with large proportions, assumptions of normality
were not justified as the proportions were negatively skewed.
Therefore, the logit transform of one minus each proportion
(i.e. log[(1 − p)/p]) was used in the meta-analyses as a normal-
izing transformation. The results were then back-transformed
to the natural scale for presentation. A test of statistical hetero-
geneity was performed for each meta-analysis and a random
effects model was fitted. Numerator values of ‘0’ (only in
specificity) were replaced with ‘0.5’. Pooled values were cal-
culated for all radiotracers and each separately based on sub-
group analysis. Subgroups were defined based on (a) study
population (AD vs. HC and/or MCI), and (b) the method used
for assessing PET uptake (visual interpretation vs. SUV-based
quantification). All meta-analyses were conducted using the
Metan procedure in Stata v. 11.0.
Results
Study identification and selection
The search conducted in EMBASE and MEDLINE returned
1,978 references and the Cochrane library returned five. Two
additional articles were returned from PubMed, and two from
the reference list of Newberg et al. [22]. The total number of
abstracts after removal of duplicates was 1,561. These ab-
stracts were screened using the inclusion criteria and 103
articles were considered eligible to be read in full. Nine arti-
cles were considered eligible for inclusion [14, 18–25] and
the remaining 92 articles were excluded; the reasons for ex-
clusion are given in Fig. 1. Figure 1 presents the data using a
four-phase flow diagram as recommended in the PRISMA
statement [32].
Study characteristics
Technical details of the included studies are presented in
Tables 1 and 2. Five of the included studies investigated
florbetapir [19–23], two investigated florbetaben [18, 25]
and two investigated flutemetamol [14, 24]. In total, there
Table 2 Analyses used in the included studies
Reference Reconstruction
method
PET corrections mentioned Qualitative
assessment
Quantitative
assessment
Reference
region
Template
Attenuation Scatter Random Decay Dead
time
Motion
[18] Iterative Yes Yes No Yes Yes No Three-grade
scale/
majority
SUVr Cerebellar
cortex
MNI MRI
singles-
subject
brain
template
using SPM
[19] Iterative Yes Yes Yes Yes No Yes Binary scale/
agreement
SUVr Whole
cerebellum
Talairach space
template
using
PMOD
[20] Iterative No No No No No No Binary scale/
majority
SUVr Whole
cerebellum
Talairach space
template
using
SPM
[14] Iterative No No No Yes No Yes Binary scale/
agreement
SUVr Cerebellar
cortex
Unclear
[21] Iterative Yes Yes Yes No No No None SUVr Whole
cerebellum
MNI T1
template
using SPM
[22] Iterative Yes No No No No No Binary scale/
agreement
Not included Cerebellum No
[23] Iterative No No No No No No Binary scale/
majority
Not included Cerebellum/
occipital
cortex
AV-133 PET
template
[24] Filtered back
projection
or iterative
No No No No No No Binary scale/
agreement
SUVr Cerebellar
cortex
MNI space
[25] Iterative Yes No No No No No Three-grade
scale/
unspecified
SUVr Cerebellar
cortex
Unclear
MNIMontreal Neurological Institute, SUVr standardized uptake value ratio, SPM statistical parametric mapping
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were 662 participants in the included studies, with a median
number per study of 59 (interquartile range 40–62). The char-
acteristics of the PETscans, such as administered dose, uptake
period and scan duration, were similar among studies using
the same radiotracer. However, most studies did not provide
information regarding the specific reconstruction algorithms
used. There was limited but varied information provided on
corrections made to the data prior to reconstruction.
The methods for reporting the PET scans were similar
among the nine studies with eight reporting qualitative results,
and seven quantitative. Six of the studies used a binary system
to analyse the qualitative results, with two studies using the
three-point system negative, minor and significant amyloid
presence (Table 2). All studies reported the use of the stan-
dardized uptake value ratio (SUVr), in five using as a refer-
ence the whole cerebellum and in four the cerebellar cortex
(Table 2), a simple semiquantitative analysis method [33].
Only three studies used a predefined cut-off value for deter-
mining whether the SUVr was amyloid-positive or amyloid-
negative. In the remaining studies, the cut-off value was cal-
culated using the optimum cut-off approach [34, 35].
All studies except two [5, 20] used clinical examination to
establish the diagnosis and all reported the results of the Mini-
Mental State Examination (MMSE). In the majority of studies
the mean MMSE score for AD patients was approximately 23
[6–9, 18, 19, 24, 25] and in only one study was the mean
MMSE score below 18 [10, 20], indicating that the majority
of the included patients clinically had MCI as classified by the
MMSE (Table 3).
QUADAS assessment of methodological quality
Each of the included studies was ranked according to the
QUADAS description provided in Supplementary Table 1.
The results are presented in Fig. 2. Two studies scored ‘yes’
for all 12 items [18, 25]. All nine studies scored ‘yes’ for five
items (questions 4, 7, 11, 12 and 14). The QUADAS items
scoring lowest were 2, 3 and 9.
The inclusion and exclusion criteria (item 2) were
clearly described in most studies. Where studies re-
ceived an ‘unclear’ ranking, this was due to the omis-
sion of the recruitment period. The delay between the
Table 4 Outcome data for meta-analysis
Reference Type of analysis Radiotracer Study groups No. of patients
AD HC Others included AD Non-AD
With
positive
PET
With
negative
PET
With
positive
PET
With
negative
PET
[18] Visual Florbetaben HC vs. AD 78 68 0 62 16 6 62
Quantitative Florbetaben HC vs. AD 78 68 0 66 12 6 62
[19] Visual Florbetapir HC vs. AD 13 21 0 11 2 13 8
Visual Florbetapir HC vs. MCI vs. AD 13 21 12 MCI 11 2 19 14
Quantitative Florbetapir HC vs. MCI vs. AD 13 21 12 MCI 12 1 3 30
[20] Visual Florbetapir HC vs. MCI vs. AD 29 12 5 MCI, 13 OD 36 3 0 20
Quantitative Florbetapir HC vs. MCI vs. AD 29 12 5 MCI, 13 OD 38 1 0 20
[14] Visual Flutemetamol HC vs. AD 36 41 0 35 1 6 35
HC vs. MCI vs. AD 36 41 68 MCI 35 1 35 74
Quantitative Flutemetamol HC vs. AD 36 41 0 34 2 7 34
HC vs. MCI vs. AD 36 41 68 MCI 34 2 35 74
[21] Quantitative Florbetapir HC vs. AD 12 11 13 MCI 11 1 9 15
[22] Visual Florbetapir HC vs. AD 19 21 0 18 1 1 20
[23] Visual Florbetapir HC vs. AD 10 5 0 9 1 0 5
[24] Visual Flutemetamol HC vs. AD 27 15 0 25 2 1 14
HC vs. MCI vs. AD 27 15 20 MCI 25 2 10 25
Quantitative Flutemetamol HC vs. AD 27 15 0 25 2 1 14
HC vs. MCI vs. AD 27 15 20 MCI 25 2 11 24
[25] Visual Florbetaben HC vs. AD 30 32 0 29 1 5 27
HC vs. MCI vs. AD 30 32 20 MCI 29 1 17 35
Quantitative Florbetaben HC vs. AD 30 32 0 29 1 5 27
HC healthy control, AD Alzheimer’s disease, MCI mild cognitive Impairment, OD other dementia
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reference and index tests (item 3) was specified as less
than 4 weeks in only three of the studies. One of the
remaining studies specified a delay longer than 4 weeks,
and the rest were unclear on the timing between the
two. Items 6 and 7 refer to the adequacy of the
description provided by the authors to allow replication
of the index and reference test, respectively. Generally,
the description of the index test was adequate, but three
studies made no mention of immobilization devices or
motion correction. For item 7, eight studies [14, 18, 19,
22, 24, 25] provided references to standard clinical di-
agnosis tests, and one study [20] provided details of the
post-mortem method. All studies provided specific de-
tails about withdrawals, or the results were presented for
the same number of participants as originally entered
the study.
Meta-analysis
The pooled estimates with 95 % confidence intervals (CI) for
sensitivity, specificity, and positive and negative likelihood
ratios are presented in Table 5. The results for sensitivity by
all subgroups ranged from 89 % to 97 %, while for specificity
the values rangedmore widely, from 63% to 93%. The values
for both sensitivity and specificity were similar for both visual
and quantitative analysis. Overall, sensitivity was higher than
specificity for all subgroups, except for the visual/florbetaben/
HC-vs.-AD subgroup, which had similar values for sensitivity
(89 %, 95 % CI 55–98 %) and specificity (89 %, 95 % CI 81–
94%). The negative likelihood ratios were all smaller than 0.2
and some were <0.1 indicating almost no likelihood of AD. In
contrast, there was great variability in the positive likelihood
ratios with the lowest value for florbetapir in a mixed popula-
tion (1.5) and using visual analysis, and the highest value for
florbetapir in a mixed population but using quantitative anal-
ysis (10.2). However, the wide CIs obtained mean that it is
difficult to select the best method of analysis with certainty.
Fig. 1 Flow chart of study selection
Fig. 2 Methodological quality
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Discussion
This systematic review was designed to investigate the accu-
racy of three new radiotracers in the diagnosis of AD by their
ability to identify amyloid beta plaques in vivo. The objectives
were to investigate the quality of available studies, compare
the technical characteristics and perform a meta-analysis to
examine the sensitivity and specificity of the included tracers.
In general, the methodological quality assessed using
QUADAS characteristics was good. Many of the omissions
were related to inadequacies of reporting rather than deficien-
cies in trial design. Where the reference test design scored
badly, this was often related to a lack of information on patient
immobilization or motion correction techniques. Patients with
AD may be less able to follow instructions, such as to remain
still during the scan [36]. Head motion during a PET scan can
affect both visual interpretation and quantitative analysis [36];
therefore, the inclusion of appropriate head fixation devices or
motion correction methods is an important aspect of study
design.
The PET imaging protocol can be a source of variability in
the results especially when quantitative analysis is performed
[37]. Whilst previous systematic reviews and meta-analyses
with non-FDG radiotracers identified large variations in scan-
ning protocols [29, 38], technical characteristics were gener-
ally comparable between the included studies. The adminis-
tered dose, uptake period and scan duration were identical
across all studies of the same radiotracer. The technical simi-
larity of the studies can be partially attributed to the involve-
ment of the manufacturers as sponsors [14, 20, 23, 24] or
training providers [19], or the adoption of published protocols
by the authors [21, 22]. The scanner models varied among
Table 5 Pooled estimates with 95 % confidence interval for sensitivity, specificity, and positive and negative likelihood ratios
Type of
analysis
Radiopharmaceutical Study groups No. of
studies
Sensitivity (95 % CI)
(%)
Specificity (95 % CI)
(%)
Likelihood ratio (95 % CI)
Positive Negative
Visual Florbetaben HC vs. AD 2 89 (55–98) 89 (81–94) 7.5 (4.3–
13.2)
0.12 (0.02–
0.62)
HC vs. MCI vs.
AD
1 97 (79–99.5) 67 (54–79) 3.0 (2.0–4.4) 0.05 (0.01–
0.34)
Florbetapir HC vs. AD 3 90 (75–96) 81 (24–98) 4.4 (0.3–
59.4)
0.17 (0.06–
0.44)
HC vs. MCI vs.
AD
2 90 (78–96) 81 (8–99.5) 1.5 (1.0–2.1) 0.16 (0.03–
0.72)
Flutemetamol HC vs. AD 2 95 (85–98) 87 (75–94) 7.3 (3.7–
14.6)
0.06 (0.02–
0.18)
HC vs. MCI vs.
AD
2 95 (85–98) 69 (61–76) 3.1 (2.4–3.9) 0.08 (0.03–
0.23)
Visual All HC vs. AD 7 90 (82–95) 85 (68–94) 6.1 (2.4–
15.6)
0.12 (0.06–
0.24)
All HC vs. MCI vs.
AD
5 93 (87–96) 66 (52–77) 2.5 (1.8–3.7) 0.10 (0.06–
0.20)
Quantitative Florbetaben HC vs. AD 2 91 (67–98) 87 (81–94) 7.8 (4.6–
13.6)
0.15 (0.09–
0.25)
HC vs. MCI vs.
AD
0 NA NA NA NA
Florbetapir HC vs. AD 1 92 (59–99) 63 (42–79) 2.4 (1.4–4.2) 0.13 (0.02–
0.89)
HC vs. MCI vs.
AD
2 96 (84–99) 93 (81–97) 10.2 (3.4–
30.2)
0.05 (0.01–
0.18)
Flutemetamol HC vs. AD 2 94 (84–98) 85 (73–92) 6.1 (3.2–
11.6)
0.07 (0.03–
0.19)
HC vs. MCI vs.
AD
2 94 (84–98) 68 (60–75) 2.9 (2.3–3.8) 0.09 (0.04–
0.24)
Quantitative All HC vs. AD 5 90 (83–94) 84 (71–91) 5.5 (3.1–9.9) 0.13 (0.08–
0.20)
All HC vs. MCI vs.
AD
4 94 (88–97) 79 (62–89) 3.5 (2.2–5.6) 0.07 (0.03–
0.16)
HC healthy control, AD Alzheimer’s disease, MCI mild cognitive Impairment, NA not available
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centres, or were not specified, which would be expected for
radiotracers used in clinical practice.
An important concept in both visual and quantitative
amyloid PET interpretation is that of amyloid positivity.
Although differences between studies exist, in both vi-
sual and quantitative assessment, positivity was defined
based on the presence or absence of tracer uptake in the
brain cortical regions in relation to a reference region
believed not to accumulate amyloid, most commonly the
cerebellum. A negative scan will display a clear image
of the corpus callosum and pons in a midline sagittal
slice, and transverse slices will display normal white
matter patterns [11, 39]. Quantitative analysis has been
advocated over visual interpretation in patients in whom
the detection of small amounts of amyloid beta in early
disease stages is needed as well as for monitoring the
effect of amyloid beta-cleaving drugs [6, 18]. The rea-
son for the latter is that treatments intended to remove
amyloid beta plaques may have modest effects on the
amyloid PET signal that are not apparent by visual com-
parison of scans [12, 40]. It should be noted that visual
analysis is usually performed using a binary scale while
quantitative analysis usually involves receiver operating
characteristic analysis without prespecified cut-off values
in most cases. As a result these data will be subject to
over-fitting possibly resulting in sensitivity and specific-
ity values that are overly optimistic [13, 35]. On the
other hand, visual interpretation depends on the ob-
server’s experience and lacks a clear cut-off value be-
tween normal and pathological findings. It should be
noted that in almost all cases of visual assessment, mul-
tiple readers had to reach agreement for a scan to be
classified as positive or negative. This is contrary to
everyday clinical practice and will have an effect on
diagnostic accuracy.
Most studies used similar visual and quantitative analysis
methods with variations on the use of an atlas or template for
identifying regions of the brain. The type of atlas used affects
the anatomical accuracy, in particular whether a single-subject
atlas is used, or one derived from multiple subjects [41].
Approximately half the studies used the cerebellum as the
reference region and half the cerebellar cortex for calculating
SUVr, and in most cases a binary yes/no answer was used for
the visual analysis. The cerebellum is considered an appropri-
ate reference region as post-mortem histopathology has shown
low levels of amyloid plaques in this area [42].
The meta-analysis of diagnostic accuracy provided 15
additional pooled outcome estimates with 95 % CIs.
The results suggest no noticeable differences in sensitiv-
ity and specificity among the different agents. This may
be a result of the small sample sizes and wide CIs.
Sensitivity values were higher for most subgroups,
while specificity was, on average, lower. The sensitivity
and specificity results for visual and quantitative analy-
ses were very similar. For both types of analysis, the
inclusion of participants with MCI generally improved
the sensitivity of the test but worsened the specificity.
The use of a combination of both analysis methods has
not been tested. The specificity of a test will also be
affected by the age of the study subjects as the accu-
mulation of amyloid deposits increases with age without
necessarily affecting cognitive function [43]. Studies
recruiting younger HC (<60 years old) [14, 24] will
show increased specificity as the percentage of amyloid
positivity in this population is almost 0 % [43]. As
there were no significant differences among the different
radiotracers included, no specific radiotracer can be rec-
ommended based on the results of this analysis.
The gold standard method for definitive diagnosis of AD is
histopathological analysis of post-mortem brain tissue.
Clinical diagnostic methods, such as the MMSE and the
Clinical Dementia Rating, which allow a diagnosis of proba-
ble AD, have a varied sensitivity and specificity. A meta-
analysis of the MMSE concluded that this test has modest
accuracy, and is most appropriate for ruling out dementia in
a primary care setting. The MMSE was able to correctly dis-
tinguish patients with dementia from healthy subjects with a
pooled sensitivity of 76.1 % (95 % CI 75.3–77.9 %) and a
pooled specificity of 88.6 % (95 % CI 87.5–89.6 %) [44]. The
aim of amyloid tracers is to provide a method to identify
amyloid plaques in vivo, where previously this has only been
possible post mortem, and allow physicians to diagnose AD
with greater accuracy early in the disease course. The low
sensitivity and specificity obtained with clinical diagnostic
methods could cause false-positive and false-negative find-
ings in studies that use suchmethods as the reference standard.
However, studies using post-mortem analysis also have draw-
backs, such as the length of time between the index test and
the post-mortem examination, and the associated procedural
cost [20].
There are a variety of alternative imaging and biomarker
techniques that can be used to provide complementary infor-
mation to improve the accuracy in the diagnosis of AD. Two
meta-analyses calculated the diagnostic accuracy of alterna-
tive neuroimaging techniques (MRI, CT, SPECT, and FDG
and 11C-PiB PET) and cerebrospinal fluid (CSF) biomarkers
CSFAβ1–42, CSF Ttau and CSF Ptau) [43, 45]. The results are
presented in Table 6 in comparison with those calculated in
this meta-analysis for the AD vs. HC group. With the excep-
tion of 18F-FDG and 11C-PiB PET, the sensitivity of amyloid
PET imaging is generally higher for both visual and quantita-
tive analysis methods than with other biomarkers and imaging
modalities. The specificity of quantitative analysis of amyloid
PET imaging is comparable to that of other methods.
However, it should be noted that in the meta-analysis by
Bloudek et al. [45] the results from a wide range of tests were
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pooled; for example, studies with HMPAO, IMP and ECD
SPECT were combined in the SPECT category, without ad-
dressing their technical and methodological aspects.
Therefore, based on the current evidence of diagnostic ac-
curacy, the use of amyloid PET imaging cannot be advocated
in preference to other existing diagnostic tests. There remains
discussion over the most appropriate position (if any) of am-
yloid PET imaging in the clinical pathway. In 2011, the
National Institute on Aging – Alzheimer’s Association
workgroups on diagnostic guidelines for Alzheimer’s disease
recommended updated criteria for the diagnosis of AD. These
criteria do not include the use of any biomarker tests in the
routine diagnostic process for AD, as the authors concluded
that the core criteria provide sufficient diagnostic accuracy,
and that more research is required, particularly regarding stan-
dardization and availability of the tests [6]. In 2014, the
International Working Group for New Research Criteria for
the Diagnosis of Alzheimer’s Disease proposed updated
guidelines for the diagnosis of typical AD [1], updating their
original 2007 criteria [46]. These criteria include in vivo evi-
dence of AD pathology, requiring one of the CSF biomarker
tests, amyloid PET imaging, or genetic tests, in addition to
clinical criteria [1]. In 2012, the European Federation of
Neurological Societies proposed guidelines on the use of neu-
roimaging in the diagnosis of dementia [47], which did not
include the use of amyloid imaging in the routine clinical
setting. They concluded that amyloid scans are likely to find
clinical utility in patients with MCI, in patients with atypical
symptoms, and for differentiating between AD and frontal-
temporal lobe dementia [47]. However, the low specificity
of beta-amyloid PET imaging in mixed populations of AD
and MCI patients challenges this approach. Finally, in 2013,
the Amyloid Imaging Task Force in association with the
Society of Nuclear Medicine and Molecular imaging and the
Alzheimer’s Association proposed appropriate use criteria for
amyloid PET imaging [48]. They considered the use of
amyloid PET imaging in a list of ten situations, with three
considered an appropriate use of the technique: atypical pre-
sentation of AD, atypical age of onset and unexplained MCI
[48]. Consensus agreement on the appropriate use of the tech-
niques has not yet been reached.
There were limitations to our study. The analysis was car-
ried out on reported data from the included studies, instead of
data from individual patients. This would have added bias to
the systematic review and meta-analysis as no accuracy
checks could be carried out. Additionally, as is common with
studies on imaging techniques that use ionizing radiation, the
numbers of patients included in most studies was small.
Conclusion
This systematic review and meta-analysis found no marked
differences in the diagnostic accuracy of the three beta-
amyloid radiotracers. All tracers perform better when used to
discriminate between patients with AD and HC. The sensitiv-
ity and specificity for quantitative and visual analysis are com-
parable to those with other imaging or biomarker techniques
used to diagnose AD. Further research is required to identify
the combination of tests that provides the highest sensitivity
and specificity, and to identify the most suitable position for
the tracer in the clinical pathway.
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